Findings

What do systematic reviews say?

4 questions · 4 findings · 3 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 2 · 50%Moderate 2 · 50%High 0 · 0%

Monthly pegloticase vs placebo

Withdrawals due to adverse events · participants with tophi in gout

Monthly pegloticase probably leads to higher number of participant withdrawals due to adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Interventions for tophi in gout 2021 · Cochrane Headline outcomes only
RR 8.19 [1.12, 59.71]
1 study · 127 participants
Moderate

Pegloticase every two weeks (biweekly) vs placebo

Withdrawals due to adverse events · participants with tophi in gout

Pegloticase every two weeks (biweekly) probably leads to higher number of participant withdrawals due to adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Interventions for tophi in gout 2021 · Cochrane Headline outcomes only
RR 7.59 [1.04, 55.55]
1 study · 128 participants
Moderate

Shock wave therapy vs placebo

Number of participant withdrawals due to adverse events or treatment intolerance · rotator cuff disease

Shock wave therapy showed no clear difference in number of participant withdrawals due to adverse events or treatment… compared with placebo (low certainty).

1 finding from 1 review

Shock wave therapy for rotator cuff disease with or without calcification 2020 · Cochrane Headline outcomes only
RR 0.75 [0.43, 1.31]
7 studies · 581 participants
Low

Calcium channel blockers vs placebo

Withdrawals due to adverse events · patients with Raynaud's phenomenon

Calcium channel blockers showed no clear difference in number of withdrawals due to adverse events Number of participants… compared with placebo (low certainty).

1 finding from 1 review

Calcium channel blockers for primary and secondary Raynaud's phenomenon 2017 · Cochrane Headline outcomes only
RR 1.3 [0.51, 3.33]
2 studies · 63 participants
Low